# Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA

> **NCT01204138** · PHASE2 · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01204138
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-09
- **Primary completion:** 2011-08
- **Final completion:** 2011-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** decision of sponsor to withdraw before initiation; 0 patients enrolled
- **Last updated:** 2016-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204138, "Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01204138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*